Breaking News


CombiMatrix Announces Contract With Galaxy Health Network

CombiMatrix Announces Contract With Galaxy Health Network

Will Provide Diagnostic Laboratory Services to Physicians, Hospitals, Large
Member Base

IRVINE, Calif., Jan. 23, 2014 (GLOBE NEWSWIRE) -- CombiMatrix Corporation
(Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based
testing services for developmental disorders and cancer diagnostics, today
announced that it has entered into a contractual agreement with Galaxy Health
Network for coverage of CombiMatrix's diagnostic laboratory services.

Galaxy Health Network, based in Arlington, TX, has a provider base of more
than 400,000 directly contracted physicians, 2,700 hospitals and 47,000
ancillary providers. Its member base has currently more than 3.5 million
covered lives. These members now have access to CombiMatrix's suite of
molecular diagnostic solutions and comprehensive clinical support –
specializing in prenatal, miscarriage and pediatric healthcare.

Mark McDonough, President and Chief Executive Officer of CombiMatrix, noted
that the partnership with Galaxy is another opportunity for CombiMatrix to
broaden its payor geographic reach. "This agreement further expands our reach
throughout the country providing much wider access to our entire portfolio of
testing services, including our CombiSNP chromosomal microarray test.

"Our partnership with Galaxy allows us to jointly educate physicians in the
Galaxy network about the advantages of chromosomal microarray testing,"
McDonough said. "We believe our services are a vital addition to important
health networks like Galaxy and look forward to a significant and growing
commercial and clinical relationship."

About Galaxy Health Network

Privately-held Galaxy Health Network was founded as Managed Care Inc. in 1993
through the purchase of the assets of AUGNET, a California-based Preferred
Provider Organization. In 1998, Managed Care Inc changed the name of its
provider network to Galaxy Health Network. Today, Galaxy Health Network has
grown its provider base to over 400,000 physicians, 2,700 hospitals and 47,000
ancillary providers – all directly contracted, and brings together Managed
Care Professionals with over five decades of collective experience for the
purpose of providing expert assistance and guidance in the containment of
medical costs.

About CombiMatrix Corporation

CombiMatrix Corporation provides valuable molecular diagnostic solutions and
comprehensive clinical support for the highest quality of care – specializing
in miscarriage analysis, prenatal and pediatric healthcare. CombiMatrix offers
comprehensive testing services for the detection of genetic abnormalities at
the DNA level, beyond what can be identified through traditional
methodologies. The Company performs genetic testing utilizing advanced
technologies, including microarray, FISH, PCR and G-Band chromosome analyses.
Additional information about CombiMatrix is available at
or by calling 1-800-710-0624.

Safe Harbor Statement under the Private Securities Litigation Reform Act of

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995. These statements are based upon our current expectations, speak only
as of the date hereof and are subject to change. All statements, other than
statements of historical fact included in this press release, are
forward-looking statements. Forward-looking statements can often be identified
by words such as "anticipates," "expects," "intends," "plans," "goal,"
"predicts," "believes," "seeks," "estimates," "may," "will," "should,"
"would," "could," "potential," "continue," "ongoing," "objective," similar
expressions, and variations or negatives of these words and include, but are
not limited to, statements regarding the access to our services for Galaxy
Health Network physicians. These forward-looking statements are not guarantees
of future results and are subject to risks, uncertainties and assumptions that
could cause our actual results to differ materially and adversely from those
expressed in any forward-looking statement The risks and uncertainties
referred to above include, but are not limited to: use of our services by
Galaxy Health Network physicians; market acceptance of CMA as a superior
method of molecular diagnostic testing; our ability to successfully expand the
base of our customers and strategic partners, add to the menu of our
diagnostic tests in both of our primary markets, develop and introduce new
tests and related reports, optimize the reimbursements received for our
testing services, and increase operating margins by improving overall
productivity and expanding sales volumes; our ability to successfully
accelerate sales, allow access to samples earlier in the testing continuum,
steadily increase the size of our customer rosters in both developmental
medicine and oncology; our ability to attract and retain a qualified sales
force; rapid technological change in our markets; changes in demand for our
future products; legislative, regulatory and competitive developments; general
economic conditions; and various other factors. Further information on
potential factors that could affect our financial results is included in our
Annual Report on Form 10-K, Quarterly Reports of Form 10-Q, and in other
filings with the Securities and Exchange Commission. We undertake no
obligation to revise or update publicly any forward-looking statements for any
reason, except as required by law.

CONTACT: Company Contact:
         Mark McDonough
         President & CEO, CombiMatrix Corporation
         Tel (949) 753-0624
         Investor Contact:
         Matt Clawson
         Allen & Caron
         Tel (949) 474-4300
         Media Contact:
         Len Hall
         VP, Media Relations
         Allen & Caron
         Tel (949) 474-4300

CombiMatrix Corporation
Press spacebar to pause and continue. Press esc to stop.